AC Immune Announces the Selection of Tau Small Molecules for Clinical Development in Alzheimer’s disease
AC Immune SA, a Swiss- based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that several Tau Morphomer candidates have demonstrated target-specific reduction of pathological Tau and cognitive and functional improvement in proof-of-concept studies in Alzheimer’s disease.